Company Contents
Quick Facts & Snapshot
Summary
The global Biopsy Devices market is entering a consolidation-driven growth phase, supported by rising cancer incidence, image-guided procedures, and minimally invasive diagnostics. Leading Biopsy Devices market companies are expanding integrated portfolios and service ecosystems to capture share. From 2025 to 2032, the market is projected to grow from US$ 3.90 Billion to US$ 6.19 Billion, at a 6.80% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
The ranking of Biopsy Devices market companies is based on a composite score that blends quantitative and qualitative indicators. Core metrics include estimated 2025 Biopsy Devices revenue, five-year revenue trajectory, and share within core segments such as needle-based biopsy, vacuum-assisted systems, and guidance technologies. Additional weight is assigned to installed base size, breadth of product and software portfolios, geographic coverage, and depth of clinical and technical service networks. Technology differentiation, including use of robotics, real-time imaging integration, and smart disposables, is evaluated alongside regulatory track record and pipeline robustness. Strategic factors capture M&A activity, partnership networks with hospitals and imaging OEMs, and ability to secure long-term service and consumables contracts. Each company receives a normalized score; leaders combine scale, innovation, and recurring revenue strength across key regions.
Top 10 Companies in Biopsy Devices
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
BD (Becton, Dickinson and Company)
BD is a global medtech leader providing comprehensive biopsy solutions spanning core needles, vacuum-assisted systems, and procedural consumables.
Hologic, Inc.
Hologic specializes in women’s health, integrating breast imaging, biopsy systems, and analytics into unified diagnostic workflows.
B. Braun Melsungen AG
B. Braun is a diversified German healthcare company with a strong portfolio of biopsy needles and instruments for multiple specialties.
Argon Medical Devices, Inc.
Argon Medical Devices provides interventional radiology-focused biopsy solutions and specialty needles for oncology and vascular procedures.
Cook Medical LLC
Cook Medical focuses on minimally invasive devices, including a wide range of endoscopic and pulmonary biopsy instruments.
Cardinal Health, Inc.
Cardinal Health is a major distributor that also offers private-label biopsy needles and procedure kits to large health systems.
Devicor Medical Products, Inc. (a Leica Biosystems company)
Devicor, within Leica Biosystems, offers specialized breast biopsy devices and tissue markers tightly linked to pathology workflows.
BIOPSYBELL S.r.l.
BIOPSYBELL is an Italian manufacturer specializing in disposable biopsy needles and bone marrow devices with flexible OEM services.
STERIS plc
STERIS provides infection-prevention and endoscopy solutions, including single-use biopsy accessories for GI and pulmonary procedures.
Olympus Corporation
Olympus is a global endoscopy leader offering biopsy forceps and accessories leveraging its massive GI and respiratory installed base.
SWOT Leaders
BD (Becton, Dickinson and Company)
SWOT Snapshot
Broad biopsy portfolio across multiple specialties, extensive global distribution, and strong manufacturing reliability.
Complex, diversified organization can slow decision-making and focused product innovation in niche biopsy segments.
Expanding oncology capacity in emerging markets and increased shift toward minimally invasive, image-guided biopsy procedures.
Aggressive price competition from regional manufacturers and continued reimbursement pressure on consumable biopsy devices.
Hologic, Inc.
SWOT Snapshot
Market-leading breast health franchise with integrated imaging, biopsy, and analytics platforms and strong brand recognition.
High exposure to breast-focused procedures and mature U.S. markets limits diversification and growth resilience.
Global expansion of breast screening programs and adoption of 3D-guided biopsy in underpenetrated regions.
Competing imaging vendors bundling biopsy systems and potential changes to screening guidelines impacting biopsy volumes.
B. Braun Melsungen AG
SWOT Snapshot
Strong European hospital relationships, diversified biopsy needle range, and robust quality reputation.
Limited brand visibility in North American biopsy devices compared with U.S.-based competitors.
Growing cancer diagnostics infrastructure in Middle East, Africa, and Latin America favor established European suppliers.
Local low-cost entrants in developing markets and supply-chain disruptions affecting needle and instrument logistics.
Biopsy Devices Market Regional Competitive Landscape
North America remains the largest regional market, driven by high cancer screening rates, advanced imaging infrastructure, and robust reimbursement. BD, Hologic, Argon Medical Devices, and Cardinal Health dominate, while Devicor benefits from integration with Leica pathology. Health systems favor Biopsy Devices market companies that can bundle devices, disposables, and service contracts.
Europe shows fragmented but sophisticated demand, with strong positions for B. Braun, BIOPSYBELL, and Olympus alongside BD and Hologic. Public tendering and strict quality regulations favor established Biopsy Devices market companies with proven clinical evidence. Growth is supported by expanded lung and colorectal cancer screening and centralized oncology networks.
Asia Pacific is the fastest-growing region, underpinned by rising cancer incidence, expanding middle-class access, and large investments in hospital infrastructure. Olympus and BD leverage broad installed bases, while Cook Medical and Hologic selectively target premium urban centers. Many Biopsy Devices market companies are forming local manufacturing or distribution partnerships to address price sensitivity.
Latin America presents mid-sized but rapidly formalizing demand, with Brazil and Mexico leading procedure growth. B. Braun, BIOPSYBELL, BD, and Cook Medical compete through regional distributors and training programs. Currency volatility and uneven reimbursement make value-oriented offerings attractive, favoring Biopsy Devices market companies with flexible pricing and service models.
The Middle East and Africa region is smaller but strategically important, with oncology capacity expanding in Gulf Cooperation Council countries and select African hubs. B. Braun, BD, and BIOPSYBELL strengthen presence via government tenders and center-of-excellence partnerships. Biopsy Devices market companies that provide clinician education, maintenance support, and reliable logistics gain competitive advantage.
Biopsy Devices Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Developing robotic-assisted, image-guided biopsy platforms that automate needle positioning and trajectory planning to improve accuracy and reduce procedure time.
Creates nano-textured biopsy needles enabling higher-quality tissue cores with reduced trauma, targeting premium segments and partnerships with Biopsy Devices market companies.
Offers cloud-native AI software that predicts optimal biopsy sites from imaging data and integrates with multiple biopsy systems via open APIs.
Provides low-cost, IoT-enabled biopsy devices with real-time tracking of utilization and consumables, aimed at resource-constrained hospitals in emerging markets.
Developing handheld, ultrasound-integrated biopsy devices with smart guidance and on-device decision support for community and ambulatory care settings.
Biopsy Devices Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Biopsy Devices market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Biopsy Devicesmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.